Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labat AfricaJSE:LAB Earnings per Share (Diluted) is R0.13 as of Nov. 2025. The stock has 5 warning signs investors should review. Among 787 Drug Manufacturers companies, Labat Africa ranks better than 77.26% on this metric.
Labat Africa's EPS (Basic) for the
six
months ended in Nov. 2025 was R0.04.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Nov. 2025 was R0.13.
During the past 3 years, the average EPS without NRIGrowth Rate was 31.20% per year.
During the past 13 years, Labat Africa's highest 3-Year average EPS without NRI Growth Rate was 31.20% per year. The lowest was -58.40% per year. And the median was -13.90% per year.
Labat Africa (JSE:LAB) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Labat Africa Earnings per Share (Diluted) Related Terms
Labat Africa Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Labat Africa's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSE:LAB vs ZTS, UTHR, VTRS: Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Labat Africa's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labat Africa PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labat Africa's PE Ratio distribution charts can be found below:
* The bar in red indicates where Labat Africa's PE Ratio falls into.
Labat Africa Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Labat Africa's Earnings Per Share (Diluted) for the fiscal year that ended in May. 2024 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Nov. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was R0.13
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of R0.13 mean?
Labat Africa (JSE:LAB) has a Earnings per Share (Diluted) of R0.13 as of Nov. 2025. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Labat Africa and its competitors. According to the industry distribution chart, Labat Africa ranks #179 out of 787 companies in the Drug Manufacturers industry, placing it in the top 22.7%.
Is Labat Africa's Earnings per Share (Diluted) too high?
Labat Africa's current Earnings per Share (Diluted) is R0.13. Based on the distribution chart, Labat Africa ranks #179 out of 787 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Labat Africa's Earnings per Share (Diluted) compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labat Africa ranks #179 out of 787 companies for Earnings per Share (Diluted). This places Labat Africa in the top 23% of its industry — outperforming the majority of peers. The industry median Earnings per Share (Diluted) is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.60, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Labat Africa and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labat Africa's current Earnings per Share (Diluted) is R0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labat Africa stock overvalued right now?
Based on GuruFocus' analysis, Labat Africa (JSE:LAB) is currently considered Possible Value Trap. The stock's GF Value™ is R0.18, compared to a current price of R0.03 — trading 83.3% below its estimated fair value. The current Earnings per Share (Diluted) is R0.13. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Labat Africa (JSE:LAB), the current Earnings per Share (Diluted) is R0.13 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Labat Africa Ltd is an investment holding company. Through its subsidiaries, the company operates in the following segments; Technology, Head office, and Healthcare. The Technology segment manufactures and distributes integrated circuits South African Micro - Electronic Systems. Head office operations provide management services, logistics and seeks further investment opportunities for the Group. The Healthcare segment generates maximum revenue for the company and focusses on medical cannabis industry in South Africa. Geographically, the company carries out its business operations in South Africa.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:LAB has been successfully added to your 
